FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2793832384> ?p ?o ?g. }

• W2793832384 endingPage "232595821876084" @default.
• W2793832384 startingPage "232595821876084" @default.
• W2793832384 abstract "To analyze the efficacy and safety of dolutegravir/rilpivirine (DTG/RPV) in HIV-infected patients who switched from any other antiretroviral therapy (ART).Open-label, multicenter study including patients who switched to DTG/RPV between February 2015 and February 2016. Efficacy (HIV RNA <50 copies/mL), adverse events, and metabolic changes at 24 weeks were analyzed.A total of 104 participants were included, who switched for the following reasons: toxicity/intolerance (42.3%), convenience (27.8%), and drug interactions (17.3%). Prior regimens are protease inhibitor (56.7%), integrase strand transfer inhibitor (26.9%), and non-nucleoside reverse transcriptase inhibitor (16.3%). Efficacy at 24 weeks was 88.4% (intention to treat) and 96.8% (per protocol). Triglyceride levels were reduced, on average, by 12.7% and a mean decrease of 9.0% in the glomerular filtration rate was observed as well ( P values of .003 and .002, respectively), whereas total cholesterol, HDL cholesterol, LDL cholesterol, creatinine, and glutamic-pyruvic transaminase remained unchanged. No patient discontinued due to adverse events.Dolutegravir/RPV is effective and safe in long-term HIV-infected patients under any prior ART. Toxicity, convenience, and interactions were the main reasons for changing. At 24 weeks, the lipid profile improved with a decrease in triglycerides." @default.
• W2793832384 created "2018-03-29" @default.
• W2793832384 creator A5025610151 @default.
• W2793832384 creator A5029391761 @default.
• W2793832384 creator A5031073935 @default.
• W2793832384 creator A5034884631 @default.
• W2793832384 creator A5035687272 @default.
• W2793832384 creator A5046963059 @default.
• W2793832384 creator A5068149370 @default.
• W2793832384 creator A5072571178 @default.
• W2793832384 creator A5078511977 @default.
• W2793832384 creator A5083369464 @default.
• W2793832384 creator A5087791132 @default.
• W2793832384 date "2018-01-01" @default.
• W2793832384 modified "2023-10-17" @default.
• W2793832384 title "Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study" @default.
• W2793832384 cites W1692190376 @default.
• W2793832384 cites W2015101591 @default.
• W2793832384 cites W2051004506 @default.
• W2793832384 cites W2085167526 @default.
• W2793832384 cites W2214278004 @default.
• W2793832384 cites W2531283301 @default.
• W2793832384 cites W2608989554 @default.
• W2793832384 cites W2609668389 @default.
• W2793832384 cites W2624821515 @default.
• W2793832384 cites W2690342936 @default.
• W2793832384 doi "https://doi.org/10.1177/2325958218760847" @default.
• W2793832384 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6748491" @default.
• W2793832384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29529910" @default.
• W2793832384 hasPublicationYear "2018" @default.
• W2793832384 type Work @default.
• W2793832384 sameAs 2793832384 @default.
• W2793832384 citedByCount "24" @default.
• W2793832384 countsByYear W27938323842018 @default.
• W2793832384 countsByYear W27938323842019 @default.
• W2793832384 countsByYear W27938323842020 @default.
• W2793832384 countsByYear W27938323842021 @default.
• W2793832384 countsByYear W27938323842022 @default.
• W2793832384 countsByYear W27938323842023 @default.
• W2793832384 crossrefType "journal-article" @default.
• W2793832384 hasAuthorship W2793832384A5025610151 @default.
• W2793832384 hasAuthorship W2793832384A5029391761 @default.
• W2793832384 hasAuthorship W2793832384A5031073935 @default.
• W2793832384 hasAuthorship W2793832384A5034884631 @default.
• W2793832384 hasAuthorship W2793832384A5035687272 @default.
• W2793832384 hasAuthorship W2793832384A5046963059 @default.
• W2793832384 hasAuthorship W2793832384A5068149370 @default.
• W2793832384 hasAuthorship W2793832384A5072571178 @default.
• W2793832384 hasAuthorship W2793832384A5078511977 @default.
• W2793832384 hasAuthorship W2793832384A5083369464 @default.
• W2793832384 hasAuthorship W2793832384A5087791132 @default.
• W2793832384 hasBestOaLocation W27938323841 @default.
• W2793832384 hasConcept C126322002 @default.
• W2793832384 hasConcept C142462285 @default.
• W2793832384 hasConcept C159047783 @default.
• W2793832384 hasConcept C159641895 @default.
• W2793832384 hasConcept C197934379 @default.
• W2793832384 hasConcept C2522874641 @default.
• W2793832384 hasConcept C2776408679 @default.
• W2793832384 hasConcept C2777302000 @default.
• W2793832384 hasConcept C2777351918 @default.
• W2793832384 hasConcept C2778163477 @default.
• W2793832384 hasConcept C2778375690 @default.
• W2793832384 hasConcept C2778390639 @default.
• W2793832384 hasConcept C2778723075 @default.
• W2793832384 hasConcept C2778913445 @default.
• W2793832384 hasConcept C2779502633 @default.
• W2793832384 hasConcept C2780040827 @default.
• W2793832384 hasConcept C2780306776 @default.
• W2793832384 hasConcept C29730261 @default.
• W2793832384 hasConcept C2993143319 @default.
• W2793832384 hasConcept C3013748606 @default.
• W2793832384 hasConcept C71924100 @default.
• W2793832384 hasConcept C90924648 @default.
• W2793832384 hasConcept C98274493 @default.
• W2793832384 hasConceptScore W2793832384C126322002 @default.
• W2793832384 hasConceptScore W2793832384C142462285 @default.
• W2793832384 hasConceptScore W2793832384C159047783 @default.
• W2793832384 hasConceptScore W2793832384C159641895 @default.
• W2793832384 hasConceptScore W2793832384C197934379 @default.
• W2793832384 hasConceptScore W2793832384C2522874641 @default.
• W2793832384 hasConceptScore W2793832384C2776408679 @default.
• W2793832384 hasConceptScore W2793832384C2777302000 @default.
• W2793832384 hasConceptScore W2793832384C2777351918 @default.
• W2793832384 hasConceptScore W2793832384C2778163477 @default.
• W2793832384 hasConceptScore W2793832384C2778375690 @default.
• W2793832384 hasConceptScore W2793832384C2778390639 @default.
• W2793832384 hasConceptScore W2793832384C2778723075 @default.
• W2793832384 hasConceptScore W2793832384C2778913445 @default.
• W2793832384 hasConceptScore W2793832384C2779502633 @default.
• W2793832384 hasConceptScore W2793832384C2780040827 @default.
• W2793832384 hasConceptScore W2793832384C2780306776 @default.
• W2793832384 hasConceptScore W2793832384C29730261 @default.
• W2793832384 hasConceptScore W2793832384C2993143319 @default.
• W2793832384 hasConceptScore W2793832384C3013748606 @default.
• W2793832384 hasConceptScore W2793832384C71924100 @default.
• W2793832384 hasConceptScore W2793832384C90924648 @default.
• W2793832384 hasConceptScore W2793832384C98274493 @default.

• next